| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
| Targets |
Semilicoisoflavone B targets multiple molecular pathways. The compound inhibits beta-secretase-1 (BACE1) expression and activity, thereby reducing amyloid beta (Abeta) secretion. Semilicoisoflavone B decreases BACE1 expression mainly through increasing PPARgamma expression and inhibiting STAT3 phosphorylation. The compound also suppresses proinflammatory cytokine production, downregulates TLR4 expression, and diminishes reactive oxygen species generation. In oral cancer cells, semilicoisoflavone B induces apoptosis through ROS production and downregulation of MAPK and Ras/Raf/MEK signaling. The compound also causes cell cycle arrest at the G2/M phase and downregulates cell cycle regulators such as cyclin A and CDKs.
|
|---|---|
| ln Vitro |
Semilicoisoflavone B demonstrates potent in vitro activity across multiple biological systems. The compound suppresses proinflammatory cytokine production, downregulates TLR4 expression, and diminishes reactive oxygen species generation in vitro. In oral cancer cells, semilicoisoflavone B induces apoptosis through ROS production and downregulation of MAPK and Ras/Raf/MEK signaling. The compound causes cell cycle arrest at the G2/M phase and downregulates cell cycle regulators such as cyclin A and cyclin-dependent kinases (CDKs). Semilicoisoflavone B inhibits sorbitol formation in rat lens incubated with high glucose concentrations. The compound reduces amyloid beta (Abeta) secretion by inhibiting BACE1 expression and activity. Its activity is concentration-dependent.
|
| ln Vivo |
In vivo activity of semilicoisoflavone B has been less extensively characterized compared to its in vitro activity. As a naturally occurring isoflavone, the compound would be expected to have oral bioavailability, but comprehensive in vivo studies have not been widely reported. The compound's ability to inhibit BACE1 and reduce Abeta secretion suggests potential for the treatment of Alzheimer's disease. Its anti-inflammatory and antioxidant properties suggest potential for various inflammatory conditions. Semilicoisoflavone B's anticancer activity in vitro suggests potential for cancer therapy. However, in vivo efficacy studies in animal models have not been extensively published. The compound is primarily used as a research tool for studying various biological pathways.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for semilicoisoflavone B can be performed to characterize its activity against various targets. BACE1 inhibition assays involve incubating the enzyme with a fluorogenic substrate and varying concentrations of the compound, with fluorescence measured to determine IC50 values. PPARgamma activation can be assessed using cell-based reporter assays. STAT3 phosphorylation inhibition can be measured by Western blot or ELISA. Antioxidant activity can be assessed using DPPH or ABTS radical scavenging assays. Anti-inflammatory activity can be evaluated by measuring cytokine production in LPS-stimulated cells. Each assay is performed under appropriate conditions with positive and negative controls. The compound's purity (typically ≥98%) is confirmed by HPLC.
|
| Cell Assay |
In vitro cellular assays for semilicoisoflavone B are performed using various cell lines depending on the biological activity being studied. For anti-inflammatory assays, macrophages or microglial cells are stimulated with LPS and treated with varying concentrations of the compound, and cytokine production (TNF-alpha, IL-1beta, IL-6) is measured by ELISA. For anticancer assays, oral cancer cells or other cancer cell lines are treated with the compound, and cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is measured using annexin V/propidium iodide staining or caspase activity assays. Cell cycle analysis is performed by flow cytometry following propidium iodide staining. ROS production is measured using fluorescent probes such as DCFH-DA. Cytotoxicity is assessed in parallel to ensure specificity.
|
| Animal Protocol |
In vivo animal studies for semilicoisoflavone B have not been extensively reported in the public domain. As a naturally occurring isoflavone, the compound would be expected to have oral bioavailability, but comprehensive in vivo pharmacokinetic and efficacy studies have not been widely published. The compound is primarily used as a research tool for in vitro studies. Animal models of Alzheimer's disease, cancer, or inflammation could potentially be used to evaluate semilicoisoflavone B's in vivo efficacy, but such studies have not been extensively reported. Standard toxicology assessments in animals would include monitoring of body weight, clinical observations, and histopathological examination of tissues. Further research is needed to determine whether semilicoisoflavone B's in vitro activities translate to in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of semilicoisoflavone B have not been extensively characterized in the public domain. As an isoflavone, the compound would be expected to be metabolized by intestinal microbiota and hepatic enzymes. Isoflavones typically have moderate oral bioavailability and undergo extensive first-pass metabolism. The compound's molecular weight and chemical properties are consistent with its flavonoid structure. Comprehensive pharmacokinetic parameters including half-life, volume of distribution, clearance, and oral bioavailability have not been reported for semilicoisoflavone B. The compound's stability in solution and under various storage conditions has been characterized. Further pharmacokinetic studies are needed to fully understand the compound's absorption, distribution, metabolism, and elimination.
|
| Toxicity/Toxicokinetics |
Semilicoisoflavone B is intended for laboratory research use only and has not undergone comprehensive toxicology testing. As a naturally occurring isoflavone found in licorice, which is consumed in the human diet, the compound may have a favorable safety profile. However, the compound's toxicity at research-use concentrations has not been extensively characterized. Standard in vitro cytotoxicity assays in cell lines are typically performed alongside efficacy studies to rule out nonspecific toxicity. In vivo, animals would be monitored for signs of toxicity if the compound were to be evaluated in animal studies. Comprehensive toxicological characterization including genotoxicity and repeated-dose toxicity studies has not been reported in the public domain. The compound is not approved for human use and is strictly intended for research purposes.
|
| References | |
| Additional Infomation |
Semi-isoflavone B belongs to the 7-hydroxyisoflavone class of compounds. Its chemical name is 2',2'-dimethyl-2'H,4H-3,6'-bis(xylene-4-one), with hydroxyl groups substituted at the 5, 7, and 8' positions. It has been isolated from licorice (Glycyrrhiza uralensis). Semi-isoflavone B is a plant metabolite and an EC 1.1.1.21 (aldehyde reductase) inhibitor. It has been reported to exist in licorice (Glycyrrhiza uralensis), licorice aspera, and other organisms with relevant data. See also: Licorice (Glycyrrhiza uralensis) root (part).
Semilicoisoflavone B is a naturally occurring isoflavone found in the roots of Glycyrrhiza uralensis Fisch. It exhibits diverse pharmacological effects including anti-inflammatory, antioxidant, antiviral, and anticancer properties. The compound reduces amyloid beta (Abeta) secretion by inhibiting BACE1 expression and activity through increasing PPARgamma expression and inhibiting STAT3 phosphorylation. Semilicoisoflavone B induces apoptosis in oral cancer cells through ROS production and downregulation of MAPK and Ras/Raf/MEK signaling, causing G2/M cell cycle arrest. The compound has not entered clinical trials and has not received regulatory approval. It is available from research chemical suppliers for non-clinical research purposes only. Semilicoisoflavone B is a valuable research tool for studying inflammation, cancer, and neurodegenerative diseases. |
| Molecular Formula |
C20H16O6
|
|---|---|
| Molecular Weight |
352.33744
|
| Exact Mass |
352.094
|
| CAS # |
129280-33-7
|
| PubChem CID |
5481948
|
| Appearance |
Light yellow to green yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
615.5±55.0 °C at 760 mmHg
|
| Melting Point |
131 - 134 °C
|
| Flash Point |
225.5±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.683
|
| LogP |
4.48
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LWZACZCRAUQSLH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16O6/c1-20(2)4-3-10-5-11(6-15(23)19(10)26-20)13-9-25-16-8-12(21)7-14(22)17(16)18(13)24/h3-9,21-23H,1-2H3
|
| Chemical Name |
5,7-dihydroxy-3-(8-hydroxy-2,2-dimethylchromen-6-yl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~141.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8382 mL | 14.1908 mL | 28.3817 mL | |
| 5 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL | |
| 10 mM | 0.2838 mL | 1.4191 mL | 2.8382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
